Related Experiment Video
Updated: Jun 8, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process?
Dominica Zentner1, David Hunt, William Chan
11Department of Cardiology, Royal Melbourne Hospital, Melbourne VIC, Australia. dominica.zentner@mh.org.au
Insights
Patients with end-stage kidney disease and aortic stenosis (AS) face worse outcomes. Early aortic valve replacement (AVR) is recommended for these patients once moderate to severe AS is detected.
Area of Science:
- Cardiology
- Nephrology
- Valvular Heart Disease
Background:
- Previously observed accelerated aortic stenosis (AS) progression in end-stage kidney disease (CKD 5D) patients.
- CKD 5D patients with AS exhibit a faster disease progression compared to controls.
Purpose of the Study:
- To prospectively follow a cohort of CKD 5D patients with AS.
- To determine major event-free survival (aortic valve replacement or death) in CKD 5D patients with AS compared to controls.
Main Methods:
- Re-matched CKD 5D cohort (n=27) to a control cohort (n=27) based on aortic valve area (AVA).
- Utilized AVA as the primary matching variable due to its significance in AS progression rate.
Main Results:
- 100% of CKD 5D patients underwent aortic valve replacement (AVR) or died.
- 63% of control patients underwent AVR or died; 9 remained event-free.
Conclusions:
- Controls demonstrated significantly greater major event-free survival (P=0.001).
- Suggests early AVR consideration for CKD 5D patients with moderate to severe AS, irrespective of symptoms.
Background:
We have previously demonstrated an increased rate of progression of aortic stenosis (AS) in patients with end-stage kidney disease (CKD 5D) compared to controls. We sought to follow prospectively a CKD 5D cohort with AS and determine major event-free survival. Follow-up was terminated once all CKD 5D subjects had undergone aortic valve replacement (AVR) or died. Our aim was to determine whether the increased rate of progression resulted in shorter major event-free (AVR or death) survival as compared to controls.
Methods:
We re-matched our original CKD 5D cohort (n = 27) to a control cohort (n = 27) based on aortic valve area (AVA) at completion of the prior study. This was done as CKD 5D and AVA were the only statistically significant variables with respect to rate of progression.
Results:
All the CKD 5D patients (100%) underwent surgery or died during the follow-up period. In contrast, 17 (63%) of the controls underwent surgery or died. Of the remaining 10 controls, nine remain alive and free of AVR and one was lost to follow-up.
Conclusion:
The controls displayed greater major event-free survival (P = 0.001), suggesting a need to consider patients with CKD 5D and AS for early AVR once echocardiographic evidence of moderate to severe AS is present, regardless of symptoms.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Kidney Transplant I: Introduction
Acute Kidney Injury I: Introduction
